Tag:

MedImmune

Latest Headlines

Latest Headlines

AstraZeneca unit expands China operations

AstraZeneca's research arm MedImmune said it will spend $50 million to expand production in China, and will also expand its manufacturing partnership with WuXi AppTec.

MedImmune joins GSK, Vanderbilt U in Human Vaccines Project

AstraZeneca's MedImmune is joining the likes of Vanderbilt University and GlaxoSmithKline as a member of the Human Vaccines Project, the company announced Tuesday. The public-private partnership, incubated at the International AIDS Vaccine Initiative (IAVI), aims to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers "by decoding the human immune system."

MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug

AstraZeneca's MedImmune has licensed a toll-like receptor agonist from 3M, in the hopes that intratumoral injection of the candidate will allow the compound to be retained in cancerous tumors, which would improve its tolerability and provide immune system activation.

UPDATED: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology

AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.

AstraZeneca's MedImmune gets RSV candidate fast-tracked

Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus to market--and one just picked up a regulatory boost.

Wuxi-MedImmune JV sees CFDA accept RA mAb for review

An Investigational New Drug application for WuXi PharmaTech and MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis was accepted for review by the China Food and Drug Administration, the company said this week, marking a milestone in a development partnership started less than three years ago.

AstraZeneca shells out $150M for cancer Dx outfit Definiens

AstraZeneca wants to build up its oncology presence, and its latest acquisition could help the company on its way. The drugmaker's MedImmune division shelled out $150 million upfront and additional milestone payments for Definiens, a diagnostic outfit with imaging technology that identifies biomarkers in tumor tissue and provides a more accurate way to assess tissue samples.

AstraZeneca shells out $150M for cancer Dx outfit Definiens

AstraZeneca wants to build up its oncology presence, and its latest acquisition could help the company on its way. The drugmaker's MedImmune division shelled out $150 million upfront and additional milestone payments for Definiens, a diagnostic outfit with imaging technology that identifies biomarkers in tumor tissue and provides a more accurate way to assess tissue samples.

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.

AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.
'